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Abstract
Objectives: Actinomycosis is a chronic suppurative granulomatous infection caused by the Actinomyces genus. 
Orocervicofacial actinomycosis is the most common form of the disease, seen in up to 55% of cases. All forms 
of actinomycosis are treated with high doses of intravenous penicillin G over two to six weeks, followed by oral 
penicillin V. Large studies on cervicofacial actinomycosis are lacking. Therefore proper guidelines for treatment 
and treatment duration are difficult to establish. The aim of this study is to establish effective treatment and treat-
ment duration for orocervicofacial actinomycosis.
Study design: A Pubmed and Embase search was performed with the focus on treatment and treatment duration 
for cervicofacial actinomycosis. The hospital records of all patients presenting to our department with head and 
neck infection from January 2000 to December 2010 were reviewed, retrospectively. The following data were col-
lected: age, gender, clinical presentation, aetiology, duration of symptoms, microbiological findings, treatment, 
and duration of treatment. The treatment and treatment duration is subsequently compared to the literature. 
Results: The literature search provided 12 studies meeting the inclusion criteria. All studies were retrospective in 
nature. Penicillin or amoxicillin/clavulanic acid are the preferred antibiotic regimens found in the literature. Most 
of our patients were treated with a combination of penicillin G 12 million units/day and metronidazol 500 mg 3/
day, most commonly for a duration of 1 – 4 weeks, being shorter than the 3 – 52 weeks reported in the literature.
Conclusion: When actinomycosis is suspected, our review has shown that a surgical approach in combination with 
intravenous penicillin and metronidazol until clinical improvement is seen, followed by oral antibiotics for 2 – 4 
weeks is generally efficient.
Key words: Actinomycosis, actinomyces, actinomycosis treatment, cervicofacial infection, actinomycosis diag-
nosis, head and neck infection.
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Introduction
Actinomycosis is a chronic suppurative granuloma-
tous infection caused by the Actinomyces genus. These 
are non-spore-forming, anaerobic, or microaerophilic 
gram-positive (1) bacilli. The pathogenic Actinomyces 
species are only found in humans, and are commensals 
of the oropharynx, gastrointestinal tract, and female 
genital tract (1). The Actinomyces species are generally 
of low pathogenicity, but can cause disease when there 
is a portal of entry, typically in the mucosa of the gas-
trointestinal tract, anywhere from the mouth to the rec-
tum (1). Once these organisms invade tissue, they form 
tiny clumps, called grains or sulfur granules (2). It is 
now rare but was common in the preantibiotic era (3).
A. israelli is the most common human pathogen and is 
found in most clinical presentations (4). Cultures with 
Actinomyces species are often accompanied by other 
organisms, such as Actinobacillus actinomycetemcomi-
tans, Eikenella corrodens, Fusobacterium, and Bacter-
oides species (3). These organisms facilitate infection by 
establishing a microaerophilic environment (3). Orocer-
vicofacial actinomycosis is the most common form of 
the disease, seen in up to 55% of cases (5,6). Patients 
frequently present with chronic soft tissue swelling (4). 
They can also present with abscesses, woody fibrosis, 
and sinus discharge of sulfur granules (3). The swellings 
are firm, and often lead to misdiagnosis of malignancy 
(4,7). Infection can spread directly to adjacent muscles 
and bones (8). Especially the mandible is reported to 
be involved in bone disease (9). According to a study 
by Brook et al. (10), when diagnosing orocervicofacial 
actinomycosis, one should also consider the following 
diagnosis: abscess by other typical bacteria, cyst, neo-
plasm, tuberculosis, or nocardiosis. Demonstration of 
Gram-positive filamentous organisms and sulphur gran-
ules on histological examination is strongly supportive 
of a diagnosis of actinomycosis (4). However, granules 
are not specific to actinomycosis (11). For definitive di-
agnosis, direct isolation of the organisms from a clinical 
specimen or from sulphur granules is necessary (4). The 
most appropriate clinical specimens are samples of pus, 
tissue, or sulphur granules. Antibiotics are the corner-
stone of treatment (4). All forms of actinomycosis are 
treated with high doses of intravenous penicillin G over 
two to six weeks, followed by oral penicillin V (10). 
Surgical treatment may be necessary if there is exten-
sive necrotic tissue, sinus tracts, fistulas, or if patients 
do not respond to medical treatment (4). It may also be 
needed if malignancy cannot be excluded (10). 
Large studies on cervicofacial actinomycosis are lack-
ing. Therefore proper guidelines for treatment and treat-
ment duration are difficult to establish. The aim of the 
current study is to map patient demographics, disease 
characteristics, diagnosis, and treatment in all patients 
admitted to our department from January 2000 to De-
cember 2010 with isolated Actinomyces spp. in their pus. 
The treatment and treatment duration is subsequently 
compared to the literature in order to establish a more 
efficient treatment regimen.
Material and Methods
The hospital records of all patients presenting with head 
and neck infection from January 2000 to December 
2010 were reviewed, retrospectively. The patients were 
identified using the hospital database. Only patients 
with positive microbial culture for Actinomyces spp. 
were included. The records of 19 patients remained for 
analysis. The following data were collected: age, gen-
der, clinical presentation, aetiology, duration of symp-
toms, microbiological findings, treatment, and duration 
of treatment. 
A Pubmed and Embase search was performed. The 
main focus of this search was to determine treatment 
and treatment duration for cervicofacial actinomycosis. 
(Mesh) terms included: ‘actinomycosis’, ‘actinomyces’, 
‘cervicofacial’, ‘head’, ‘face’, ‘skull’, ‘neck muscles’. 
All studies meeting the following criteria were includ-
ed: only cervicofacial actinomycosis, age > 18 years, 
case reports describing 2 or more patients with cervi-
cofacial actinomycosis, English language. Cases where 
actinomycosis was diagnosed in 2 different locations 
simultaneously were excluded. Only immunocompe-
tent patients were analyzed, excluding patients infected 
with the human immunodeficiency virus, tuberculosis, 
non-Hodgkin lymphoma, post-renal transplantation, 
badly regulated diabetes mellitus, and chronic granulo-
matous disease. Only studies published after 1990 were 
included in order to ensure analysis of the most recent 
treatment modalities, and to subsequently make a com-
parison to our study population. These criteria left 12 
articles for inclusion.
Results
The study population consisted of 10 males and 9 females 
with a mean age of 37.2 (SD: ± 17.4) years. The youngest 
patient was 19 years and the oldest 85 years. There was 
no significant difference in age between male and female 
patients. All patients were immunocompetent.
-Symptoms
All patients presented with a swelling. In 9 (47.4%) cas-
es the swelling was progressive in size and in 3 (15.8%) 
cases the swelling was recurrent. Seventeen patients 
(89.5%) complained of pain. Swelling of soft tissue was 
most frequently located in the mandibular region (6 of 
19; 31.6%). Other locations consisted of the cheek (2 of 
19; 10.5%) (Fig. 1.), the buccal region (2 of 19; 10.5%), 
the infratemporal region (1 of 19; 5.3%), the infraorbital 
region (1 of 19; 5.3%), and the sublingual region (1 of 
19; 5.3%). One patient developed necrotizing osteomy-
elitis of the mandible.
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Fig. 1. Swelling of the cheek in a patient with actinomycosis. Note 
the possible beginning of a sinus tract. 
The duration of symptoms prior to admission ranged 
from 4 days to 1 year (44.2 ± 87.9 days). Most patients 
(12 of 19; 63.2%) had symptoms for 7 days or less. Three 
patients had symptoms lasting 1 – 3 months, and 4 pa-
tients had symptoms lasting more than 2 months to one 
year prior to admission.  During this period, 9 patients 
(47.4%) received oral antibiotics, mostly consisting of 
amoxicillin or amoxicillin/clavulanic acid. 
-Aetiology 
The most commonly reported aetiology prior to start of 
symptoms were removal of a tooth (10 of 19; 52.6%), 
infected teeth (7 of 19; 36.8%), or trauma (2 of 19; 
10.5%). 
-Microbiology
The pus of eighteen patients was cultured for the pres-
ence of Actinomyces. In one patient, Actinomyces could 
not be isolated. The pus of this patient was histopatho-
logicaly analyzed and was found positive for Actinomy-
ces sp. The most frequently found species of Actinomy-
ces were A. meyeri (4 of 17; 23.5%), A. israelii (4 of 17; 
23.5%), and A. naeslundi (4 of 17; 17.6%). In 7 cases, the 
species was not specified. In 16 cases, the concomitant 
microbial flora was noted. In all patients a concomitant 
mixed anaerobic flora was retrieved. Eight patients (8 
of 16; 50.0%) had mixed infections with Streptococcus 
milleri, and seven patients (7 of 16; 43.8%) had mixed 
infections with Propionibacterium acnes. 
-Treatment
Sixteen (84.2%) patients were treated with intravenous 
antibiotics, incision and drainage of the swelling, and 
debridement of necrotic tissue, if needed. Three patients 
(15.8%) were treated as outpatients with oral AB. Intra-
venous AB treatment most frequently (10 of 19; 52.6%) 
consisted of penicillin G 12 million units/day with met-
ronidazol 500 mg 3/day. One patient didn’t improve on 
this AB regimen and was treated with ceftriaxon 2000 
mg/day and clindamycin 600 mg 3/day. In case of peni-
cillin allergy, clindamycin would be administered. An 
overview of treatment and treatment duration is pro-
vided in table 1.
Patients were discharged from hospital when clinical 
improvement was seen. Time to clinical improvement 
ranged from 1 to 46 days (SD 8.4 ± 13.2) when treated 
with intravenous AB.
-Literature search
Pubmed and Embase were searched, resulting in 1400 
and 1007 articles respectively. Of these articles, 397 
were duplicates. Relevance was based on information 
provided in the title and abstract. More than half (1076 
of 2010; 53.5%) was not useful. These studies described 
the microbiology of infections involving primarily other 
microorganisms than the Actinomyces species, used ac-
tinomycosis in the differential diagnosis, or described 
in vitro tests with Actinomyces species. Of the remain-
ing 934 articles, 322 were of foreign language, 102 in-
volved cases with non-cervicofacial actinomycosis, 278 
studies were published before the year 1990, 34 articles 
described (largely) paediatric patients, 114 reported only 
one patient, and 32 studies described actinomycosis in-
volving multiple locations, multiple microorganisms 
(e.g. an Actinomyces and tuberculosis co-infection), and 
immunocompromised or ill patients (human deficiency 
virus, poorly regulated diabetes, multiple myeloma, post-
transplantation, osteoradionecrosis). Finally, 38 articles 
were general articles on actinomycosis, not describing 
patient populations, or articles missing crucial informa-
tion important for this review. The full text could not be 
retrieved for two, possibly relevant, articles. Twelve arti-
cles remained for inclusion (See fig. 2). 
All studies were of retrospective nature. Five studies re-
ported two cases of actinomycosis (12-16). The remain-
ing studies reported cases ranging from 4 to 15 patients 
(17-23). Custal-Teixidor et al.(17) retrospectively analyzed 
15 cases, including a paediatric patient. Treatment of this 
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Table 1. Treatment of cervicofacial actinomycosis in 19 patients.
* treatment duration unknown, MU: million units.
Fig. 2. Flow chart of the articles evaluated for inclusion.
?
No of  
patients
AB administered i.v. 
(duration in days) 
AB given to patient at discharge p.o. 
(duration in days) 
Total duration of AB 
treatment in weeks (days) 
Surgical 
Treatment 
    
10 Penicillin G 12 MU/day + 
Metronidazol (1 - 16) 
Feneticillin 500 mg 4/day + 
Metronidazol 500 mg 4/day (7) 
1 – 3 (8 – 23) 10/10 
1 Penicillin G 12 MU/day + 
Metronidazol (3) 
Amoxicillin/clavulanic acid 625 mg 
4/day (14) 
2 (17) 1/1 
1 Penicillin G 24 MU/day (38) Amoxicillin 1000 mg 4/day (90) 18 (127) 1/1 
1 Amoxicillin/clavulanic acid 
1200 mg 3/day (6) 
Amoxicillin/clavulanic acid 625 mg 
3/day (10) 
2 (16) 1/1 
1 Amoxicillin/clavulanic acid 
1200 mg 4/day (2) 
Amoxicillin 1000 mg 4/day (30) 4 (32) 1/1 
1 Clindamycin 600 mg 3/day (4) Clindamycin 600 mg 3/day (7) 1,5 (11) 1/1 
1 Ceftriaxon 2000 mg/day + 
Clindamycin 600 mg 3/day 46) 
Clindamycin 600 mg 3/day (30) 11 (76) 1/1 
2 - Amoxicillin/clavulanic acid 625 mg 
3/day (18 and unknown) 
3 (18 - …*) 1/2 
1 - Amoxicillin (67) 9,5 (67) 0/1 
patient was not mentioned separately, and is included in 
the current review. Similarly, Bartkowski et al.(18) in-
cluded 3 patients < 18 years in their analysis of 15 cases. 
However, the treatment of their patients was reported 
separately. Thus, the paediatric patients were excluded. 
Different departments were involved in the treatment of 
these patients, including the department of otolaryngolo-
gy head and neck surgery (12,16, 19,20,23), dermatology 
(13), internal medicine (17), Microbioloby (18) plastic and 
reconstructive surgery (14), radiology (21), and maxillo-
facial surgery (13,18,22). Table 2 shows an overview of 
the treatment modality, treatment duration, and patient 
outcome retrieved in these 12 publications.
Discussion
The current study retrospectively reviewed all patients 
treated for cervicofacial actinomycosis from January 
2000 to December 2010. This provided 19 cases, to our 
knowledge being the largest case series described since 
1990. Actinomycosis can present as a chronic, slowly 
progressive infiltration, or as a more acute and rapidly 
progressive swelling (24). In accordance with the lit-
erature (7,13,14,16,17,21,22,25) our patients presented 
with persistent, sometimes recurrent swellings, which 
were both tender and non-tender, and non-responsive to 
short-term oral antibiotics. Most studies describe a la-
tency of infection ranging from a few weeks to over one 
year (12,14-17,20-23,26), whereas most of our patients 
presented within one week of start of symptoms. This 
can be explained by the more acute and rapidly pro-
gressive nature of the swellings seen in our population. 
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?
Author(s), year No of 
patiens
AB Treatment, i.v. and p.o., if applicable 
(duration in days) 
Total
duration in 
Weeks 
Surgical
Treatment 
Recurrence, 
No of Cases 
     
Sittitrai et al.(23) 5 Penicillin G 12 MU i.v. (42) 24 Unknown 0/5 
 Penicillin V 1 g p.o. (135)    
Woo et al.(19), 2008 6 Cephalosporin (30), Roxithromycin 150 mg/day (90) 16 6/6 0/6 
Lancella et al.(12), 2008 1
Piperacillinum/tazobactanum 2/0.25 g i.v. 3/day (6) 
Betamethasone i.v. 4mg/2ml/day (6) 
Amoxicillin/Clavulanic acid 875/125 mg p.o. 3/day (30) 
5 1/1 0/1 
1
Amoxicillin/Clavulanic acid 2/0.2 g i.v. 2/day (5) 
Amoxicillin/Clavulanic acid 875/125 mg p.o. 3/day (30) 5 1/1 0/1 
Custal-Teixidor et al.(17), 
2004* 15 
Penicillin 12 to 18 MU i.v. 
with Amoxicillin 1.5-3 g or a macrolid p.o. 24 – 52 7/15 1/15 
Bochev et al.(13), 2003 2 Penicillin 8 MU i.v. (30) 4 1/2 0/2 
Ermis et al.(14), 2001 2
Penicillin G 12 MU i.v. (10-14) 
Penicillin V 4 g p.o. (60) 10 2/2 2/2 
Belmont et al.(20), 1999 1 Penicillin p.o. 6 0/1 1/1 
2
Penicillin i.v. (5-10) 
Penicillin p.o. (28) 5 0/2 0/2 
1 Cephalexin (42) 6 Unknown 0/1 
Bartkowski et al.(18), 1998** 7 Penicillin i.v. max 45 MU/day 4 – 8 8/8 1/8 
1 Penicillin i.m. and Debecycline 3 1/1 0/1 
1 Lincomycin i.v. and Metronidazol i.v. 3 1/1 0/1 
2 Lincomycin i.v. and Biostymina p.o. 3 – 12 2/2 0/2 
1 Augmentin 375 p.o. and Metronidazol p.o. 4 1/1 1/1 
Nagler et al.(22), 1997 11 Penicillin i.v. 9-12MU/day 6 – 12 11/11 11/11 
Sa’do et al.(21), 1993 5 Bacampicillin 1500 mg/day 12 – 20 4/5 5/5 
Kawai et al.(15), 1993 1 Ampicillin 2000 mg/day i.v. and hyperbaric oxygen (10) 1,5 (10) 0/1 0/1 
1 Benzylpenicillin 1.2 MU i.v. (30?) 4? (30?) 1/1 0/1 
Gaffney et al.(16), 1993 1 Penicillin i.v. (3) and penicillin p.o. (90) 12 (93) 1/1 0.1 
 1 Amoxicillin 250 mg (5) and amoxicillin/clavulanic acid (56) 9 (61) 1/1 0/1 
Table 2. Overview of treatment of cervicofacial actinomycosis in 12 studies.
* Includes a paediatric patient, ** Patients < 18 years excluded, p.o.: per os, i.v.: intravenous, MU: million units.
Also, possibly the Dutch health care system encourages 
a low visiting threshold for patients, and quick referral 
to specialized clinics, limiting doctor’s delay.  
Diagnosis of cervicofacial actinomycosis can be very 
difficult. In a study performed by Park et al.(7), in 4 
out of 7 cases, the swelling was thought to be a malig-
nancy, and in 2 other cases, the swelling was diagnosed 
as either malignancy or granulomatous disease based 
on radiologic diagnosis. The suspicion of a malignant 
mass has also been made by other studies (15,20,21,23). 
Definitive diagnosis is best made by histopathology af-
ter excision, fine needle aspiration or biopsy, revealing 
the presence of sulfur granules (7,12,13,15,16,19,20). 
Culturing Actinomyces has proven extremely difficult 
due to the anaerobic nature of this organism, requiring 
up to 14 days of strict anaerobic incubation (24). Also, 
aerobic and anaerobic bacterial overgrowth, or possible 
suppressive effect of prior antimicrobial therapy might 
make diagnosis by culture difficult (22). Studies of neg-
ative cultures have been reported (16,17,20,22). In these 
cases diagnosis was made by histopathology. In the cur-
rent study, all cultures were positive for Actinomyces. 
The sole explanation for this finding is that this was the 
inclusion criterion. 
Penicillin remains the treatment of choice since the in-
troduction by Nichols and Herrell in 1948 (24). The ma-
jority of our patients received antibiotic treatment for a 
duration of 1 – 4 weeks, being shorter than the 3 – 52 
weeks reported in the literature (12-14,16-22). Perhaps 
this is because our patients were treated with a combi-
nation of penicillin and metronidazol, affecting a larger 
microbial spectrum, and making the environment unfa-
vourable for Actinomyces. Also, intravenous treatment 
is usually stopped and replaced by oral antibiotics when 
clinical improvement is seen, preventing prolonged in-
travenous administration of antibiotics. 
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Nagler et al. (22) hypothesized that patients with actino-
mycosis don’t respond well to antibiotic therapy before 
degranulation and curettage or lesion resection due 
to compartmentalization of the organisms within the 
granulation tissue and the sulfur granules. This sepa-
rates the organism from the blood supply and antibiotics 
administered. Surgical treatment in our patient popula-
tion was generally performed shortly after presentation. 
According to Nagler et al.(22), facilitating the effects 
of the antibiotic treatment, and, in turn, explaining the 
short treatment duration needed in our population.  
Conclusions
Actinomyces spp. are normal inhabitants of the oral mi-
crobial flora. Thus, a positive culture with Actinomyces 
spp. does not always imply the diagnosis of actinomy-
cosis. On the other hand, a negative culture does not 
exclude actinomycosis. Final diagnosis should be made 
based on clinical findings in combination with bacte-
riological and/or histopathological findings. When ac-
tinomycosis is suspected, our review has shown that 
a surgical approach in combination with intravenous 
penicillin and metronidazol until clinical improvement 
is seen, followed by oral antibiotics for 2 – 4 weeks is 
generally efficient. Nevertheless, one should always be 
aware of the indolence of this microorganism and not 
stop treatment prematurely.
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